Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (21376)	5/25/1998 11:59:00 AM
From: John O'Neill	Read Replies (1) \| Respond to of 32384

WTDEC......Regarding potential patent problem, isn't it true that most biotech patents face the "test" in court on patent infringement? It seems like Roche would need concrete damages to have a base for suing...i.e. when another party starts selling their product. A patent can be issued but found to be invalid in court. (I'm not suggesting LGND would have a problem here..but these suits can be very expensive). I believe it's a jury decision in the initial patent infringement suit (as absurd this sounds) so most decisions go on to appeal...decided by a panel of judges. JO